ReviewFrontiers in cardiovascular medicine2026
Targeting lipocalin-2 in atherosclerosis: biological functions, pathogenic mechanisms, and therapeutic potential.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis, the principal pathological underpinning of cardiovascular diseases, is a multifaceted process encompassing dysregulated lipid metabolism, chronic inflammation, oxidative stress, aberrant vascular smooth muscle cells (VSMCs) proliferation, and plaque destabilization. Lipocalin-2 (LCN-2), a pivotal member of the lipocalin superfamily, serves as a critical nexus integrating lipid metabolism with inflammatory cascades. This review systematically delineates the gene localization, protein architecture, and expression regulation of LCN-2, with a focus on its multifaceted roles and molecular mechanisms across diverse stages of atherosclerosis, including endothelial dysfunction, lipid deposition, inflammatory amplification, foam cell formation, VSMCs phenotypic switching, and plaque rupture. This work highlights the promise of LCN-2 as a diagnostic biomarker and therapeutic target, offering novel insights and strategic directions for the precise prevention and management of atherosclerosis. Given its pathogenic significance, elevated LCN-2 levels in serum, plasma, urine, and plaque tissue serve as diagnostic and prognostic biomarkers for atherosclerosis. Multiple therapeutic strategies targeting LCN-2, including gene knockout, neutralizing antibodies, small-molecule inhibitors, RNA interference and repurposed clinical drugs, have achieved encouraging anti-atherosclerotic effects in preclinical studies. Collectively, LCN-2 acts as a core molecular linker between inflammation and lipid metabolism in atherosclerosis, and targeting LCN-2 holds great potential for the early diagnosis, risk stratification and novel therapeutic intervention of atherosclerotic cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.